Y-Biologics CEO Park Young-woo Increases Stake by 0.01% via Open Market Purchase, Signaling Management Confidence

Y-Biologics CEO Park Young-woo acquired 1,900 common shares on June 23, 2026 at 13,878 KRW per share via open market purchase, raising his stake from 22.92% to 22.93%, an increase of 0.01%.
This minor insider buying reflects management confidence but has negligible impact on shareholder value given the tiny change relative to total outstanding shares.
No capital dilution or fundraising purpose; it is a routine personal market transaction.
[AI Summary]The CEO's small open market purchase signals management confidence but has limited market impact and does not alter shareholder value.